Literature DB >> 11854519

Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors.

Oender Solakoglu1, Christine Maierhofer, Georgia Lahr, Elisabeth Breit, Peter Scheunemann, Isabella Heumos, Uwe Pichlmeier, Gunter Schlimok, Ralph Oberneder, Manfred W Kollermann, Jens Kollermann, Michael R Speicher, Klaus Pantel.   

Abstract

Bone marrow is a major homing site for circulating epithelial tumor cells. The present study was aimed to assess the proliferative capacity of occult metastatic cells in bone marrow of patients with operable solid tumors especially with regard to their clinical outcome. We obtained bone marrow aspirates from 153 patients with carcinomas of the prostate (n = 46), breast (n = 45), colon (n = 33), and kidney (n = 29). Most of the patients (87%) had primary disease with no clinical signs of overt metastases [tumor-node-metastasis (TNM)-stage UICC (Union Internationale Contre le Cancer) I-III]. After bone marrow was cultured for 21-102 days under special cell culture conditions, viable epithelial cells were detected by cytokeratin staining in 124 patients (81%). The cultured epithelial cells harbored Ki-ras2 mutations and numerical chromosomal aberrations. The highest median number of expanded tumor cells was observed in prostate cancer (2,619 per flask). There was a significant positive correlation between the number of expanded tumor cells and the UICC-stage of the patients (P = 0.03) or the presence of overt metastases (P = 0.04). Moreover, a strong expansion of tumor cells was correlated to an increased rate of cancer-related deaths (P = 0.007) and a reduced survival of the patients (P = 0.006). In conclusion, the majority of cancer patients have viable tumor cells in their bone marrow at primary tumor diagnosis, and the proliferative potential of these cells determines the clinical outcome.

Entities:  

Mesh:

Year:  2002        PMID: 11854519      PMCID: PMC122350          DOI: 10.1073/pnas.042372199

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

1.  RT-PCR from archival single cells is a suitable method to analyze specific gene expression.

Authors:  G Lahr
Journal:  Lab Invest       Date:  2000-09       Impact factor: 5.662

2.  Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer.

Authors:  S Braun; K Pantel; P Müller; W Janni; F Hepp; C R Kentenich; S Gastroph; A Wischnik; T Dimpfl; G Kindermann; G Riethmüller; G Schlimok
Journal:  N Engl J Med       Date:  2000-02-24       Impact factor: 91.245

3.  Urokinase plasminogen activator receptor (uPA-R): one potential characteristic of metastatic phenotypes in minimal residual tumor disease.

Authors:  H Allgayer; M M Heiss; R Riesenberg; K U Grützner; A Tarabichi; R Babic; F W Schildberg
Journal:  Cancer Res       Date:  1997-04-01       Impact factor: 12.701

Review 4.  Detection and clinical importance of micrometastatic disease.

Authors:  K Pantel; R J Cote; O Fodstad
Journal:  J Natl Cancer Inst       Date:  1999-07-07       Impact factor: 13.506

Review 5.  The importance of being K-Ras.

Authors:  C A Ellis; G Clark
Journal:  Cell Signal       Date:  2000-07       Impact factor: 4.315

6.  Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors.

Authors:  B Gerber; A Krause; H Müller; D Richter; T Reimer; J Makovitzky; C Herrnring; U Jeschke; G Kundt; K Friese
Journal:  J Clin Oncol       Date:  2001-02-15       Impact factor: 44.544

7.  Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases.

Authors:  K Pantel; J Izbicki; B Passlick; M Angstwurm; K Häussinger; O Thetter; G Riethmüller
Journal:  Lancet       Date:  1996-03-09       Impact factor: 79.321

8.  Establishment of micrometastatic carcinoma cell lines: a novel source of tumor cell vaccines.

Authors:  K Pantel; A Dickmanns; A Zippelius; C Klein; J Shi; W Hoechtlen-Vollmar; G Schlimok; D Weckermann; R Oberneder; E Fanning
Journal:  J Natl Cancer Inst       Date:  1995-08-02       Impact factor: 13.506

9.  Individual development and uPA-receptor expression of disseminated tumour cells in bone marrow: a reference to early systemic disease in solid cancer.

Authors:  M M Heiss; H Allgayer; K U Gruetzner; I Funke; R Babic; K W Jauch; F W Schildberg
Journal:  Nat Med       Date:  1995-10       Impact factor: 53.440

10.  Tumour cell detection in the bone marrow of breast cancer patients at primary therapy: results of a 3-year median follow-up.

Authors:  N Harbeck; M Untch; L Pache; W Eiermann
Journal:  Br J Cancer       Date:  1994-03       Impact factor: 7.640

View more
  33 in total

Review 1.  Bone specific immunity and its impact on metastasis.

Authors:  Nikola Baschuk; Jay Rautela; Belinda S Parker
Journal:  Bonekey Rep       Date:  2015-04-15

2.  Isolation of circulating epithelial and tumor progenitor cells with an invasive phenotype from breast cancer patients.

Authors:  Janice Lu; Tina Fan; Qiang Zhao; Wei Zeng; Eva Zaslavsky; John J Chen; Michael A Frohman; Marc G Golightly; Stefan Madajewicz; Wen-Tien Chen
Journal:  Int J Cancer       Date:  2010-02-01       Impact factor: 7.396

3.  Dormant cancer cells retrieved from metastasis-free organs regain tumorigenic and metastatic potency.

Authors:  Mika Suzuki; Evangeline Sari Mose; Valerie Montel; David Tarin
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

Review 4.  Mechanisms of Cancer Cell Dormancy--Another Hallmark of Cancer?

Authors:  Albert C Yeh; Sridhar Ramaswamy
Journal:  Cancer Res       Date:  2015-09-09       Impact factor: 12.701

5.  The interrelating dynamics of hypoxic tumor microenvironments and cancer cell phenotypes in cancer metastasis.

Authors:  Kai Bartkowiak; Sabine Riethdorf; Klaus Pantel
Journal:  Cancer Microenviron       Date:  2011-05-31

Review 6.  Pancreatic cancer: a generalized disease--prognostic impact of cancer cell dissemination.

Authors:  D Bogoevski; T Strate; E F Yekebas; J R Izbicki
Journal:  Langenbecks Arch Surg       Date:  2008-01-17       Impact factor: 3.445

Review 7.  Tumor heterogeneity: causes and consequences.

Authors:  Andriy Marusyk; Kornelia Polyak
Journal:  Biochim Biophys Acta       Date:  2009-11-18

Review 8.  The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies.

Authors:  Jaclyn A Freudenberg; Qiang Wang; Makoto Katsumata; Jeffrey Drebin; Izumi Nagatomo; Mark I Greene
Journal:  Exp Mol Pathol       Date:  2009-05-18       Impact factor: 3.362

Review 9.  Cancer micrometastases.

Authors:  Klaus Pantel; Catherine Alix-Panabières; Sabine Riethdorf
Journal:  Nat Rev Clin Oncol       Date:  2009-06       Impact factor: 66.675

10.  Keratin 18 attenuates estrogen receptor alpha-mediated signaling by sequestering LRP16 in cytoplasm.

Authors:  Yuanguang Meng; Zhiqiang Wu; Xiaoyun Yin; Yali Zhao; Meixia Chen; Yiling Si; Jie Yang; Xiaobing Fu; Weidong Han
Journal:  BMC Cell Biol       Date:  2009-12-26       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.